The term benign breast disease (BBD) is used to describe a combination of several clinical diagnoses noted at breast biopsy. In 1985, the Cancer Committee of the College of American Pathologists reached a consensus on the type of pathologic findings included in BBD and on the grouping of the pathologic diagnoses into categories relative to the degree of invasive breast cancer risk likely to be associated with each category
12. In 1998, Fitzgibbons et al.
13 reported an updated version of the consensus definitions. Several authors have studied the risk of breast cancer associated with BBD, however, none of these authors has fully explored the independence of BBD in breast cancer risk from the known breast cancer risk factors
14-20.
There are different opinions on whether fibrocystic changes are related to malignancy 21. Fibrocystic changes are found in the lower-category benign breast disease (LC-BBD) group according to the classification of the Cancer Committee of the College of American Pathologists, and in this group of diseases (Adenosis, ductal ectasia, fibroadenoma without complex features, fibrosis, mastitis, mild hyperplasia without atypia, ordinary cysts, simple apocrine metaplasia, squamous metaplasia) increased risk of malignancy has not been reported 12,13. Likewise, Moinfar 22 reported in his book Essentials of Diagnostic Breast Pathology that fibrocystic disease is not associated with increased risk of cancer. On the other hand, in a study conducted on 11307 female patients by Wang et al. 15, LC_BBD was diagnosed in 1376 cases and cyst was detected in 674 of them. Invasive breast carcinoma developed in 264 of 674 patients with cyst diagnosis and risk of developing malignancy for cysts was determined as 1.79, while this risk was reported to be 1.42 for other LC-BBD. An elevated risk of breast cancer associated with a diagnosis of a cyst has been indicated by studies of case series 23-25. In a cytogenetic analysis of 69 FCC cases and 10 normal breast tissues by Lundin et al. 26, clonal chromosome aberration was detected in 6 FCC cases, but all normal tissues were found to have normal karyotypes. The frequency of chromosomal abnormalities found in BBD, although lower than in breast carcinoma, correlates with the corresponding risk of developing invasive carcinoma.
The molecular identification of high risk breast lesions could improve the effect of current preventive strategies and the application of selected therapeutic interventions 27,28. According to the field cancerization hypothesis, as widely reported in head and neck cancer 27,29,30, it is likely that benign breast tumors, precursors for invasive cancer and the normal appearing peritumoral tissue, may harbor molecular changes heralding early stages of cancer development 26,31. Moreover, the benign parenchyma of cancer-containing breasts and the contralateral normal epithelium in patients who experienced cancer in one breast, can share the same pattern of chromosomal abnormalities with invasive carcinoma 32.
HER-2 gene amplification is considered to contribute to the development of breast carcinoma, i.e. carcinogenesis 13,14. In a HER-2 study performed by Rohan 33 et al to determine the risk of cancer, HER-2 staining was performed by immunohistochemical methods on 74 female patients who were diagnosed with BBD and who subsequently developed malignancy and 309 female patients who did not develop malignancy, and HER-2 staining was not associated with malignancy development. In a study by Gusterson et al. 34 on 150 BBDs, none of the 22 FCC cases was reported for HER2 staining.
In this study that we aim to determine the risk of malignancy development in patients with fibrocystic changes using the HER-2 gene, it was found that there was a significant difference in the degree of staining in areas of FCC with breast tumor cases. HER-2 was positive in 7 of the FCC cases with malignancy, but no HER-2 positivity was found in any of the FCC without breast carcinoma. There was a significant difference between FCC with breast tumor cases and without tumor in terms of staining scores and it was found that HER-2 staining was more frequent in FCC areas with tumors, (χ2 = 37,079; p <0,05).
Ordinary apocrine cells are an important constituent feature of FCC. Several studies have analyzed the possible relationship between apocrine change in FCC and breast carcinoma. Thus, Foote and Stewart in a study of 300 breast cancer specimens and 200 noncancerous specimens, analyzed the frequency of apocrine epithelium 35. They found no significant difference in the frequency of apocrine change. Their conclusion was that apocrine metaplasia is unlikely a precursor of breast cancer, given the high prevalence of this feature. Furthermore, Wellings and Alpers 36 in their subgross analysis of 186 autopsy breast tissue specimen and 107 breast cancer specimens, failed to demonstrate a continuous spectrum of apocrine metaplasia to overt carcinoma. However, in this study, no staining was observed in apocrine metaplasic areas. In areas of fibrocystic, positive staining was detected in the cyst epithelium in 4 of the samples, in ductal adenosine areas in 3 of the samples. We were convinced that apocrine metaplasia has a lower risk of malignancy than cyst formation and ductal adenosis.
In this study that we conducted on FCC with tumor cases and FCC without malignancy. The number of cases was relatively low. Performing these studies in larger groups will increase their significance. In this study, we found out that HER 2 staining was significantly more positive in FCC with malignancy than without malignancy and that the risk of malignancy was higher in HER-2 positive cases by immunohistochemistry. Early diagnosis is very important in breast carcinoma. Screening programs in our country are quite common. However, these programs pose a financial burden. We therefore believe that HER-2 staining for breast biopsies will be helpful for determining malignancy potential in FCC of the breast, and that positive staining will be critical about adjustment of patient follow-up frequency according to this potential.